16
Participants
Start Date
November 18, 2020
Primary Completion Date
July 31, 2024
Study Completion Date
July 31, 2024
Botox Injectable Product
The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
No intervention (placebo)
This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
Eye Care Centre, Victoria General Hospital, Halifax
Dalhousie University
OTHER
Nova Scotia Health Authority
OTHER